Paper40940902
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.
Kawczak P and 2 others. Cancers (Basel), 2025. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma. Papers, record 40940902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940902
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References380
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28187290 | Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. | Cell | 2017 | https://conductscience.org/library/papers/28187290 | PubMed |
| 2 | 15734974 | Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. | Cancer Epidemiol Biomarkers Prev | 2005 | https://conductscience.org/library/papers/15734974 | PubMed |
| 3 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 4 | 17255361 | Inhibitory effect of tumor cell-derived lactic acid on human T cells. | Blood | 2007 | https://conductscience.org/library/papers/17255361 | PubMed |
| 5 | 37536941 | Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. | J Immunother Cancer | 2023 | https://conductscience.org/library/papers/37536941 | PubMed |
| 6 | 37146473 | Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. | Lung Cancer | 2023 | https://conductscience.org/library/papers/37146473 | PubMed |
| 7 | 34538402 | RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. | Contemp Clin Trials | 2021 | https://conductscience.org/library/papers/34538402 | PubMed |
| 8 | 35790315 | Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35790315 | PubMed |
| 9 | 37511453 | Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511453 | PubMed |
| 10 | 40243372 | Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. | Immun Inflamm Dis | 2025 | https://conductscience.org/library/papers/40243372 | PubMed |
| 11 | 38398094 | Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398094 | PubMed |
| 12 | 30576970 | Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. | Eur J Cancer | 2019 | https://conductscience.org/library/papers/30576970 | PubMed |
| 13 | 35258987 | Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial. | J Clin Oncol | 2022 | https://conductscience.org/library/papers/35258987 | PubMed |
| 14 | 28885881 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28885881 | PubMed |
| 15 | 36877893 | First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened? | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36877893 | PubMed |
| 16 | 34446053 | Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). | Radiat Oncol | 2021 | https://conductscience.org/library/papers/34446053 | PubMed |
| 17 | 27718784 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. | N Engl J Med | 2016 | https://conductscience.org/library/papers/27718784 | PubMed |
| 18 | 26406148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
| 19 | 39725966 | Current trends in sensitizing immune checkpoint inhibitors for cancer treatment. | Mol Cancer | 2024 | https://conductscience.org/library/papers/39725966 | PubMed |
| 20 | 33303578 | Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/33303578 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42401619 | Programmed cell death ligand 1(PD-L1) association in metastatic and non-metastatic oral squamous cell carcinoma: clinicopathologic and immunohistochemical study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42401619 | PubMed |
| 42121986 | Immunohistochemical Study of the Tumor Immune Microenvironment in p16-Positive and p16-Negative Oral Squamous Cell Carcinoma and Its Prognostic Implications. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42121986 | PubMed |
| 41683575 | Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41683575 | PubMed |
| 41097741 | Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41097741 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40940902
GET https://conductscience.org/api/papers/v1/40940902/references?page=2